key: cord-0986713-be4e9isy
authors: Coulon, Pierre-Gregoire; Prakash, Swayam; Dhanushkodi, Nisha R.; Srivastava, Ruchi; Zayou, Latifa; Tifrea, Delia F.; Edwards, Robert A.; Cesar, J. Figueroa; Schubl, Sebastian D.; Hsieh, Lanny; Nesburn, Anthony B.; Kuppermann, Baruch D.; Bahraoui, Elmostafa; Vahed, Hawa; Gil, Daniel; Jones, Trevor M.; Ulmer, Jeffrey B.; BenMohamed, Lbachir
title: High Frequencies of PD-1+TIM3+TIGIT+CTLA4+ Functionally Exhausted SARS-CoV-2-Specific CD4+ and CD8+ T Cells Associated with Severe Disease in Critically ill COVID-19 Patients
date: 2022-01-31
journal: bioRxiv
DOI: 10.1101/2022.01.30.478343
sha: 86ef6027d0d563da01cff8cc853bc29c80dceb4a
doc_id: 986713
cord_uid: be4e9isy

SARS-CoV-2-specific memory T cells that cross-react with common cold coronaviruses (CCCs) are present in both healthy donors and COVID-19 patients. However, whether these cross-reactive T cells play a role in COVID-19 pathogenesis versus protection remain to be fully elucidated. In this study, we characterized cross-reactive SARS-CoV-2-specific CD4+ and CD8+ T cells, targeting genome-wide conserved epitopes in a cohort of 147 non-vaccinated COVID-19 patients, divided into six groups based on the degrees of disease severity. We compared the frequency, phenotype, and function of these SARS-CoV-2-specific CD4+ and CD8+ T cells between severely ill and asymptomatic COVID-19 patients and correlated this with α-CCCs and β-CCCs co-infection status. Compared with asymptomatic COVID-19 patients, the severely ill COVID-19 patients and patients with fatal outcomes: (i) Presented a broad leukocytosis and a broad CD4+ and CD8+ T cell lymphopenia; (ii) Developed low frequencies of functional IFN-γ-producing CD134+CD138+CD4+ and CD134+CD138+CD8+ T cells directed toward conserved epitopes from structural, non-structural and regulatory SARS-CoV-2 proteins; (iii) Displayed high frequencies of SARS-CoV-2-specific functionally exhausted PD-1+TIM3+TIGIT+CTLA4+CD4+ and PD-1+TIM3+TIGIT+CTLA4+CD8+ T cells; and (iv) Displayed similar frequencies of co-infections with β-CCCs strains but significantly fewer co-infections with α-CCCs strains. Interestingly, the cross-reactive SARS-CoV-2 epitopes that recalled the strongest CD4+ and CD8+ T cell responses in unexposed healthy donors (HD) were the most strongly associated with better disease outcome seen in asymptomatic COVID-19 patients. Our results demonstrate that, the critically ill COVID-19 patients displayed fewer co-infection with α-CCCs strain, presented broad T cell lymphopenia and higher frequencies of cross-reactive exhausted SARS-CoV-2-specific CD4+ and CD8+ T cells. In contrast, the asymptomatic COVID-19 patients, appeared to present more co-infections with α-CCCs strains, associated with higher frequencies of functional cross-reactive SARS-CoV-2-specific CD4+ and CD8+ T cells. These findings support the development of broadly protective, T-cell-based, multi-antigen universal pan-Coronavirus vaccines. KEY POINTS A broad lymphopenia and lower frequencies of SARS-CoV-2-specific CD4+ and CD8+ T-cells were associated with severe disease onset in COVID-19 patients. High frequencies of phenotypically and functionally exhausted SARS-CoV-2-specific CD4+ and CD8+ T cells, co-expressing multiple exhaustion markers, and targeting multiple structural, non-structural, and regulatory SARS-CoV-2 protein antigens, were detected in severely ill COVID-19 patients. Compared to severely ill COVID-19 patients and to patients with fatal outcomes, the (non-vaccinated) asymptomatic COVID-19 patients presented more functional cross-reactive CD4+ and CD8+ T cells targeting conserved epitopes from structural, non-structural, and regulatory SARS-CoV-2 protein antigens. The cross-reactive SARS-CoV-2 epitopes that recalled the strongest CD4+ and CD8+ T cell responses in unexposed healthy donors (HD) were the most strongly associated with better disease outcomes seen in asymptomatic COVID-19 patients. Compared to severely ill COVID-19 patients and to patients with fatal outcomes, the (non-vaccinated) asymptomatic COVID-19 patients presented higher rates of co-infection with the α-CCCs strains. Compared to patients with mild or asymptomatic COVID-19, severely ill symptomatic patients and patients with fatal outcomes had more exhausted SARS-CoV-2-speccific CD4+ and CD8+ T cells that preferentially target cross-reactive epitopes that share high identity and similarity with the β-CCCs strains.

8 demographic characteristics of the COVID-19 patients with respect to age, gender, HLA-A*02:01 or 159 HLA-DRB1*01:01 distribution, disease severity, comorbidity, symptoms and symptoms onset, length of stay 160 in the hospital, pulmonary function, immunological parameters, and blood components are summarized in 161   Table 1 and Supplemental Table 1 . Fifteen liquid-nitrogen frozen PBMCs samples (blood collected pre-162 COVID-19 in 2018) from HLA-A*02:01 + /HLA-DRB1*01:01 + unexposed healthy individuals (Healthy Donor: 163 HD -8 males, 7 females; median age: 54 (20-76)) were used as controls to measure recalled SARS-CoV-164 2 cross-reactive T cell responses. 165 The class-II HLA status of each patient was first screened for HLA-DRB1*01:01 by PCR 166 (Supplemental Fig. S1A ) with the protocol described by (56), using sense primer 5'-167 TTGTGGCAGCTTAAGTTTGAAT-3' and two antisense primers: 5'-ACTGTGAAGCTCTCACCAAC-3' 168 ("primer 3a") and 5'-GGCCCGCCTCTGCTCCA-3' ("primer 3c"). For class-I HLA, the screening was first 169 performed (two-digit level) by HLA-A*02 flow staining (data not shown, mAbs clone BB7.2, BioLegend, San 170 Diego, CA). The four-digit class-I HLA-A*02:01 subtype was subsequently screened by PCR 171 (Supplemental Fig. S1B ) on blood samples from the subjects using the PCR method described previously 172 (57) (sense primer 5′-CCTCGTCCCCAGGCTCT-3′ and antisense 5′-TGGCCCCTGGTACCCGT-3′).

T cell epitopes screening, selection and peptide synthesis: Peptide-epitopes from twelve 174 SARS-CoV-2 proteins, including 27 9-mer long CD8 + T cell epitopes (ORF1ab84-92, ORF1ab1675-1683 ORF1ab2210-2218, ORF1ab2363-2371 ORF1ab5470-5478, ORF1ab6419-6427, ORF1ab6749-6757, S2-10, S691-699, S958-966, S976-984, S1000-1008, S1220-1228, E20-28, 177 E26-34, M52-60, and 16 178 13-mer long CD4 + T cell epitopes (ORF1a1350-1365 , ORF1a1801-1815 ORF1ab6420-6434, S1-13, E20-34, 180 ORF8b1-15 and N388-403) that we formerly identified were selected as described previously (1). Briefly, we first 181 identified consensus protein sequences after performing a sequence conservation analysis between SARS- Predictions, Class I Immunogenicity, Tepitool, TEPITOPEpan and NetMHC) to screen conserved CD8 + T 185 Exhausted Cross-Reactive SARS-CoV-2-Specific T cells in Severely ill COVID-19 Patients 9 cell candidate epitopes predicted to bind the 5 most frequent HLA-A class I alleles (HLA-A*01:01, HLA-186 A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-A*23:01) and conserved CD4 + T cell candidate epitopes 187 predicted to bind 5 class II alleles with large population coverage regardless of race and ethnicity, namely 188 DRB1*01:01, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB1*03:01, HLA-DRB1*04:01 (1). The Epitope 189 Conservancy Analysis tool was used to compute the degree of identity of CD8 + T cell and CD4 + T cell 190 epitopes within a given protein sequence of SARS-CoV-2 set at 100% identity level (1). Peptides were 191 synthesized as previously described (1) analysis, or for 24 hours before being transferred in IFN-γ ELISpot plates for an additional 48 hours (i.e., for a total of 72 hours stimulation in both conditions). Same isolation protocol was followed for HD samples 213 taken in 2018. Ficoll were kept in frozen in liquid nitrogen in FBS DMSO 10%; after thawing, HD PBMCs 214 were stimulated in the same manner for ELISpot assay: COVID-19 patients were first screened for their HLA status: out of 147 samples, 92 216 were DRB1*01:01 + and 71 were HLA-A*02:01 + whereas, 16 patients were screened positive for both 217 (Supplemental Fig. S1 and Supplemental Table 1 ). The ninety-two DRB1*01:01 positive individuals were 218 used to assess the CD4 + T-cell response against our SL-CoVs-conserved SARS-CoV-2-derived class-II 219 restricted epitopes by IFN-g ELISpot. Seven individuals were asymptomatic -severity score 0; 7 patients 220 had very-mild COVID-19 -severity score 1; 41 showed moderate disease -severity score 2; and 37 patients 221 developed severe or very severe symptoms, divided into 3 groups: 12 patients in ICU without mechanical 222 ventilation -severity score 3; 11 patients in ICU who required mechanical ventilation -severity score 4; and 223 14 patients who died from COVID-19 -severity score 5. 224 Similarly, we assessed the CD8 + T-cell response against our SL-CoVs-conserved SARS-CoV-2-225 derived class-I restricted epitopes in the seventy-one HLA-A*02:01 positive individuals. Seven individuals 226 were asymptomatic -severity score 0; 7 patients had very-mild COVID-19 -severity score 1; 24 showed 227 moderate disease -severity score 2; and 33 patients developed severe or very severe symptoms, divided 228 into 3 groups: 12 patients in ICU without mechanical ventilation -severity score 3; 8 patients in ICU who 229 required mechanical ventilation -severity score 4; and 13 patients who later died from COVID-19 -severity 230 score 5.

All ELISpot reagents were filtered through a 0.22 µm filter. Wells of 96-well Multiscreen HTS Plates 232 (Millipore, Billerica, MA) were pre-wet with 30% ethanol for 60 seconds and then coated with 100 µl primary 233 anti-IFN-g antibody solution (10 µg/ml of 1-D1K coating antibody from Mabtech, Cincinnati, OH) OVN at 234 4°C. After washing, the plate was blocked with 200 µl of RPMI media plus 10% (v/v) FBS for 2 hours at 235 room temperature to prevent nonspecific binding. Following the blockade, twenty-four hours 236 peptide-stimulated cells from the patients PBMCs (0.5 x 10 6 cells/well) were transferred into the ELISpot 237 coated plates. PHA stimulated or non-stimulated cells (DMSO) was used as positive or negative controls of 238 T cells activation, respectively. After incubation in a humidified chamber with 5% CO2 at 37°C for an 239 Exhausted Cross-Reactive SARS-CoV-2-Specific T cells in Severely ill COVID-19 Patients 11 additional 48 hours, cells were washed using PBS and PBS-Tween 0.02% solution. Next, 100 µl of 240 biotinylated secondary anti-IFN-g antibody (1 µg/ml, clone 7-B6-1, Mabtech) in blocking buffer (PBS 0.5% 241 FBS) were added to each well. Following a 2-hour incubation and washing, wells were incubated with 100 242 µl of HRP-conjugated streptavidin (1:1000) for 1 hour at room temperature. Lastly, wells were incubated for 243 15-30 minutes at room temperature with 100 µl of TMB detection reagent and spots were counted both 244 manually and by an automated ELISpot reader counter (ImmunoSpot Reader, Cellular Technology, Shaker 245 Heights, OH).

Flow cytometry analysis: After 72 hours of stimulation with each individual SARS-CoV-2 class-I 247 or class-II restricted peptide, PBMCs from the same 147 patients were stained for surface markers detection 248 (0.5 x 10 6 cells) and subsequently analyzed by flow cytometry (Supplemental Fig. S2) . First, the cells were 249 stained with a live/dead fixable dye (Zombie Red dye, 1/800 dilution -BioLegend, San Diego, CA) for 20 250 minutes at room temperature, to exclude dying/apoptotic cells. Cells were then stained for 45 minutes at 251 room temperature with five different HLA-A*02*01 restricted tetramers and/or five HLA-DRB1*01:01 252 restricted tetramers (PE-labelled) specific toward the SARS-CoV-2 CD8 + T cell epitopes Orf1ab2210-2218 Orf1ab4283-4291, S976-984, S1220-1228, ORF103-11 and toward the CD4 + T cell epitopes ORF1a1350-1365, S1-13, E26- Clara, CA). A total of ∼200,000 lymphocyte gated PBMCs (140,000 alive CD45 + ) were acquired by Fortessa X20 (Becton Dickinson, Mountain View, CA) and the subsequent analysis performed using FlowJo software 267 (TreeStar, Ashland, OR). Gating strategy is detailed in Supplemental Fig. S2B . the highest BLOSUM62-sum score compared to the SARS-CoV-2 epitope set as reference was selected 310 (Supplemental Table 5 ). We calculated % of identity and similarity score S s with its related SARS-CoV-2 311 epitope, for each of these CCCs peptides (Supplemental Table 5 using the ECT instead of the one found using MSA (peptides not highlighted in Supplemental Table 3 ).

Using the %id and the calculated similarity score with the SARS-CoV-2 epitopes, all related CCCs 333 best matching peptides were reported in Supplemental Table 3 . They were then evaluated based on their 334 potential of inducing a cross-reactive T cell response, as shown in Supplemental Table 4 : 335 (0): CCC best matching peptide with low to no potential to induce a cross-reactive response toward the 336 corresponding SARS-CoV-2 epitope and vice-versa (%id with the corresponding SARS-CoV-2 epitope 337 < 67% AND similarity score S s < 0.8) ; (0.5): CCC best matching peptide that may induce a cross-reactive 338 response (%id with the corresponding SARS-CoV-2 epitope ≥ 67% OR similarity score S s ≥ 0.8) ;

(1): CCC best matching peptide very likely to induce a cross-reactive response (%id ≥ 67% AND S s ≥ 0.8). 341 We took advantage of the database generated by Pedro A. Reche (64). Queries to find matching peptides 342 with our SARS-CoV-2-derived CD4 + and CD8 + epitopes were performed from the data gathered; only 343 peptides sharing a %id ≥ 67% with our corresponding SARS-CoV-2 epitope were selected (Supplemental 344 Table 7 ). The corresponding similarity score S s was calculated, and results reported in Supplemental Table   345 4.

Statistical analyses: To assess the potential linear negative relationship between COVID-19 347 severity and the magnitude of each SARS-CoV-2 epitope-specific T cell response, correlation analysis using tests. Data are expressed as the mean + SD. Results were considered statistically significant at P ≤ 0.05.

To evaluate whether the differences in frequencies of RT-PCR positivity to the four CCCs across categories 361 of disease severity was significant, we used the Chi-squared test (when comparing three groups of COVID-362 19 severity) or the Fisher's exact test (when comparing two groups of COVID-19 severity).

CoV-2-specific CD4 + T cell responses in symptomatic vs. asymptomatic COVID-19 patients (Fig. 1) . We 368 used 16 recently identified HLA-DR-restricted CD4 + T cell epitopes that are highly conserved between human 369 SARS-CoVs and animal SL-CoVs (1). We enrolled 92 non-vaccinated HLA-DRB1*01:01 + COVID-19 370 patients, genotyped using PCR (Supplemental Fig. S1 ), and divided into six groups, based on the level of 371 severity of their disease (from severity 5 to severity 0, assessed at discharge - (quantified in ELISpot assay as the number of IFN-g-spot forming cells, or "SFCs") ( Fig. 1) . 384 Overall, the highest frequencies of IFN-g-producing CD4 + T cells (determined as mean SFCs > 50 385 per 0.5 x 10 6 PBMCs fixed as threshold) were detected early in COVID-19 patients with less severe disease 386 (i.e., severity 0, 1 and 2, Figs. 1A and 1B). In contrast, the lowest frequencies of IFN-g-producing CD4 + T 387 cells directed toward SARS-CoV-2 epitopes were detected in the remaining two groups of severely ill 388 symptomatic COVID-19 patients (i.e., severity 3 and 4, mean SFCs < 50) and the group of patients with fatal 389 outcomes (i.e., severity 5, mean SFCs < 25).

To determine a potential linear correlation between the magnitude of CD4 + T cell responses directed 391 toward each of the 16 highly conserved SARS-CoV-2 epitopes and COVID-19 disease severity, we 392 performed a Pearson correlation analysis, where a negative correlation is usually considered strong when 393 the coefficient R is comprised between -0.7 and -1 (65). Except for the ORF1ab5019-5033 and ORF7a98-112 394 epitopes, we found a strong negative linear correlation between the magnitude of IFN-g-producing CD4 + T 395 cells against all the remaining 14 epitopes and the severity of COVID-19 disease (Fig. 1C) . Consequently, 396 a positive correlation existed between the magnitude of CD4 + T cell responses specific to 14 CD4 + T cell 397 epitopes and the "natural protection" seen in asymptomatic COVID-19 patients. This correlation existed 398 regardless of whether CD4 + T cells target structural or non-structural SARS-CoV-2 antigens. However, both 399 the Pearson correlation coefficient (R) (Supplemental Table 2 ) and the coefficient of determination (R 2 , Fig.   400 1C) give a measure of linearity of a possible two-way linear association but do not quantify the "magnitude" 401 of this relationship, which is given by the slope (S) of the best-fitted line (linear regression) shown in Fig. 1C .

For any T cell epitope-specific response where a negative correlation with the onset of severe symptoms is 403 significant, a strongly negative slope S indicates that the higher the initial T cell response against this epitope, 404 the lower the associated COVID-19 disease severity score. Supplemental Table 2 illustrates in 405 SARS-CoV-2-infected patients, the epitope-specific CD4 + T cell responses that were the most negatively 406 associated with subsequent severe COVID-19 (using a blue/red color code).

An early IFN-g-producing CD4 + T cell response specific to M176-190, ORF1a1350-1365 ORF612-26, and to a slightly lesser extent to ORF8b1-15, and ORF1a1801-1815, were associated with a low 409 COVID-19 severity score (i.e., negatively correlated with a R close to -1) and a very strong negative slope 410 (-41.26 < S < -28.04). Comparatively, the CD4 + T cell responses against E26-40, ORF1ab6088-6102, ORF7b8-22, 411 E20-34, ORF1ab6420-6434, ORF7a1-15 and ORF7a3-17, were also negatively associated with severe disease in 412 patients, but to a lesser degree (relatively less negative slope: -25.61 < S < -17.76) (Fig 1C and   413 Supplemental Table 2 ). In contrast, no significant correlation was found between the magnitude of IFN-g-

producing CD4 + T cell responses directed towards ORF1ab5019-5033 and ORF7a98-112 epitopes and the disease 415 severity (P > 0.05). For the ORF1ab5019-5033 and ORF7a98-112 epitopes, where the slope was comparatively 416 weak: only slightly negative with S > -10 ( Fig. 1C and Supplemental Table 2 ).

Taken together, these results demonstrate an overall lower magnitude of SARS-CoV-2-specific CD4 +

T cell responses in symptomatic and severely ill COVID-19 patients. In contrast, higher magnitudes of SARS-

CoV-2-specific CD4 + T cell responses were detected in asymptomatic COVID-19 patients. The findings 420 suggest an important role of SARS-CoV-2-specific CD4 + T cells directed against both structural and non-421 structural antigen in protection from severe COVID-19 symptoms and highlights the importance of rapidly 422 mounting strong CD4 + T cell responses directed towards SARS-CoV-2 epitopes that are highly conserved 423 between human SARS-CoVs and animal SL-CoVs.

CoV-2-specific CD8 + T cell responses in symptomatic vs. asymptomatic COVID-19 patients (Fig. 2) . We 427 used 27 recently identified HLA-A*0201-restricted CD8 + T cell epitopes that are highly conserved between 428 human SARS-CoVs and animal SL-CoVs (1). We enrolled 71 non-vaccinated HLA-A*0201 + COVID-19 429 patients, genotyped using PCR (Supplemental Fig. S1 ), and divided into 6 groups based on disease 430 severity, as stated above (i.e., severity 5 to severity 0, Table 1 and Supplemental Table 1 CD8 + T cells were detected in the 2 groups of severely ill symptomatic COVID-19 patients (i.e., severity 3 440 and 4, mean SFCs < 50) and in patients with fatal outcomes (i.e., severity 5, mean SFCs < 25). These results

suggest that, like CD4 + T cells, there was an association between low magnitudes of SARS-CoV-2-specific 442 CD8 + T cell responses and severe COVID-19 disease onset. Moreover, there was an association between 443 high magnitudes of SARS-CoV-2-specific CD8 + T cell responses and a no to low COVID-19 severity of disease. This association was regardless of whether CD8 + T cells targeted epitopes from structural, non-445 structural, or regulatory SARS-CoV-2 protein antigens.

Out of the 27 CD8 + T cell epitopes, there was a significant negative linear correlation between CD8 +

T cell responses specific to 22 epitopes and COVID-19 disease severity ( Figs. 2A and 2B ). For these 22 448 epitopes, the Pearson correlation coefficients (R) ranged from -0.8314 to -0.9541 and slopes (S) of the best-449 fitted lines comprised between -14.36 and -52.81 (Supplemental Table 2 ). For the remaining 5 epitopes 450 (ORF1ab2210-2218, ORF1ab3013-3021, ORF1ab5470-5478, S691-699, and S976-984), no significant linear correlation was 451 observed. Nonetheless, among these 5 epitopes, the slope for ORF1ab2210-2218, ORF1ab3013-3021 and 452

ORF1ab5470-5478 was comparatively less negative (S > -10) ( Fig. 2C and Supplemental Table 2 ). Also, 453 although we could not establish any significant linear correlation relationship between CD8 + T cell responses 454 against S691-699 or S976-984 and disease severity, more-complex (non-linear) associations might exist. For 455 example, the magnitude of the S976-984-specific IFN-g-producing CD8 + T cell response followed a clear 456 downside trend as the disease severity increased in severely ill symptomatic COVID-19 patients and patients 457 with fatal outcomes (i.e., severity 3, 4 and 5) ( Fig. 2A and Fig. 2C : SS976-984 = -24.77).

Taken together, these results demonstrate that in COVID-19 patients, low SARS-CoV-2-specific 459 CD8 + T cell responses were more commonly associated with severe disease onset. In contrast, higher 460 magnitudes of SARS-CoV-2-specific CD8 + T cell responses were detected in asymptomatic COVID-19 461 patients. These findings suggest that, in addition to CD4 + T cells, SARS-CoV-2-specific CD8 + T cells directed 462 against both structural and non-structural antigens play an important role in protection from COVID-19 463 severe symptoms and highlights the importance of rapidly mounting strong CD8 + T cell responses directed 464 towards SARS-CoV-2 epitopes that are highly conserved between human SARS-CoVs and animal SL-CoVs. 

466 associated with severe disease in COVID-19 patients: We next sought to determine whether the low 467 magnitude of SARS-CoV-2 specific IFN-g-producing CD4 + and CD8 + T cell responses detected in severely 468 ill and fatal COVID-19 patients was a result of an overall deficit of CD4 + and CD8 + T cells. Using a blood 469 differential test (BDT), we compared the absolute numbers of white blood cells (WBCs) and blood-derived 470 lymphocytes, ex vivo, in the six groups of COVID-19 patients (i.e., severity 0, 1, 2, 3, 4, and 5, Fig. 3A ).

Blood samples were isolated from COVID-19 patients on average 4.8 days after reporting their first 472 symptoms. A significant increase (between ∼1.5-and ∼2.6-fold) in the numbers of WBCs was detected in 473 patients with fatal outcomes, (i.e., severity 5) when compared with all the 4 other groups of COVID-19 474 patients (i.e., severity 0, 1, 2, 3 and 4; P ≤ 0.02, Fig. 3A -left panel). In addition, we found a significantly 475 lower absolute numbers of total lymphocytes circulating in the blood of patients with fatal outcomes 476 compared to patients with mild disease (severity 1 and 2: ∼1.9-and ∼2.3-fold decrease -P < 0.02) or to 477 asymptomatic patients (severity 0:

Comprehensively, the most severely ill patients (severity 3, 4 and 5) had significantly fewer blood-derived 479 lymphocytes than patients developing little to no disease (severity 0, 1 and 2). As a result, the more severe Finally, we determined the frequencies of SARS-CoV-2 tetramer-positive T cells specific to 5 different 496 CD4 + and 5 different CD8 + SARS-CoV-2-derived SL-CoVs-conserved epitopes (Fig. 4) after 72 hours of 497 corresponding peptide-stimulation (Supplemental Fig. S2) . Respectively: ORF1a1350-1365, S1-13, E26-40, M176-21 190 and ORF612-26 for the DRB1*01:01-restricted CD4 + epitopes (Fig. 4A) and Orf1ab2210-2218 S976-984, S1220-1228 and ORF103-11 for the A*02:01-restricted CD8 + epitopes (Fig. 4B) . In the most severely ill 500 patients and patients with fatal outcomes (severity 3, 4 and 5), we found a significant decrease in the 501 frequencies of tetramer-positive CD4 + T cells specific to all the 5 SARS-CoV-2 DRB1*01:01-restricted 502 epitopes compared to patients with mild disease (severity 1, 2 -P ≤ 0.01) or no disease (severity 0 -P ≤ 503 0.002) (Fig. 4A) . Similarly, we found a significant decrease in the frequencies of tetramer-positive CD8 + T 504 cells specific to 3 out of the 5 SARS-CoV-2 A*02:01-restricted epitopes (Orf1ab4283-4291, S1220-1228 and 505 ORF103-11 - Fig. 4B ) in the most severely ill symptomatic patients (severity 3, 4 and 5) compared to patients 506 with mild disease (severity 1,2 -P ≤ 0.03) or asymptomatic patients (P < 0.001). Except for ORF1ab2210-2219 507 and S976-984 epitopes (for which we showed in Fig. 2 that there was no significant negative correlation 508 between the associated IFN-g response and disease severity), the lowest frequencies of epitope-specific 509 CD4 + and CD8 + T cells were detected in the group of severely ill symptomatic COVID-19 and in patients with 510 fatal outcomes (i.e., severity 3, 4 and 5; Fig. 4 ). This contrasts with similar frequencies of EBV BMLF-1280- bulk CD3 + T cell lymphocytes numbers (affecting both CD4 + and CD8 + T cells equally) in severely ill COVID-521 19 patients was one major cause of this lymphopenia, but more importantly; (iii) that SARS-CoV-2-specific 522 CD4 + and CD8 + T cells responding to conserved epitopes from structural, non-structural and regulatory 523 protein antigens were even more reduced (particularly decreased relative to total reduction in T cells) in 

527

CD4 + and CD8 + T cells: We next determined whether the low magnitudes of SARS-CoV-2-specific IFN-g-529 producing T cell responses ( Figs. 1 and 2) and low frequencies of tetramer-positive SARS-CoV-2-specific 530 CD4 + and CD8 + T cells (Fig. 4) five structural and non-structural SARS-CoV-2 epitopes (Orf1ab2210-2218, Orf1ab4283-4291, S976-984, S1220-1228 and 537 ORF103-11, Fig. 6 ). 538 We detected significantly higher frequencies of phenotypically exhausted SARS-CoV-2-specific 539 CD4 + T cells ( Fig. 5A -up to ∼6.9-fold increase for ORF612-26-specific PD-1 + TIGIT + CD4 + T cells and up to 540 ∼7.8-fold increase for M176-190 -specific TIM-3 + CTLA-4 + CD4 + T cells) in COVID-19 patients with high severity 541 scores (i.e., severity 3, 4 and 5) compared to asymptomatic COVID-19 patients (i.e., severity 0). Similarly, 542 there were significantly higher frequencies of phenotypically exhausted SARS-CoV-2-specific CD8 + T cells 543 ( Fig. 6A -up to ∼3.6-fold increase for S1220-1228-specific PD-1 + TIGIT + CD8 + T cells and up to ∼4.6-fold 544 increase for S1220-1228-and ORF103-11-specific TIM-3 + CTLA-4 + CD8 + T cells) in severely ill COVID-19 and in 545 patients with fatal outcomes compared to asymptomatic COVID-19 patients. Overall, except for Orf1ab2210-546 2218-and S976-984 -specific-CD8 + T cells, the most severely ill patients (severity 3, 4 and 5) had significantly 547 higher frequencies of exhausted T cells co-expressing PD-1 + TIGIT + or TIM-3 + CTLA-4 than patients 548 developing little to no disease (severity 0, 1 and 2). That Orf1ab2210-2218-and S976-984-specific-CD8 + T cells 549 showed no significant higher phenotypic exhaustion in severely ill COVID-19 patients was consistent with 550 the observation that CD8 + T cell responses to these two epitopes were not associated with severe COVID-551 19 disease (Figs. 2 and 4) .

Reflecting the high frequencies of exhausted CD4 + and CD8 + T cells in severely ill COVID-19 and in 553 patients with fatal outcomes, we also detected the lowest frequencies of functional CD134 + CD138 + CD4 + T 554 cells (Fig. 5B ) and CD134 + CD138 + CD8 + T cells (Fig. 6B) in those patients. This applied to 555 CD134 + CD138 + CD4 + T cells specific to all 5 structural and non-structural SARS-CoV-2 epitopes and for 556 CD134 + CD138 + CD8 + T cells specific to 3 out of 5 structural and non-structural SARS-CoV-2 epitopes 557 (except Orf1ab2210-2218 and S976-984-specific CD8 + T cells). As expected, there was no difference in phenotypic 558 and functional exhaustion of EBV BMLF-1280-288-specific CD8 + T cells across the COVID-19 disease 559 severities (Supplemental Fig. S3B) , suggesting that the exhaustion in severely ill COVID-19 patients was 560 specific to SARS-CoV-2-specific CD4 + and CD8 + T cells.

In conclusion, the decrease in the magnitudes of IFN-g-producing SARS-CoV-2 specific T cell 562 responses and in the frequencies of tetramer-positive SARS-CoV-2-specific CD4 + and CD8 + T cells detected 563 in COVID-19 patients with high severity scores (i.e., severity 3, 4 and 5) was associated with phenotypic and 564 functional exhaustion of CD4 + and CD8 + T cells specific to those SL-CoVs-conserved epitopes, from both 565 structural and non-structural antigens.

567 patients present lower frequencies of co-infections with α-CCCs: Using RT-PCR, we examined the co-568 infection with each of the four strains of CCCs (i.e., α-CCC-NL63, α-CCC-229E, β-CCC-HKU1 and β-CCC-569 OC43) in a cohort of 84 COVID-19 patients divided into six groups with various disease severities (Fig. 7A) . 570 We found co-infections with α-CCCs strains, to be more common and significantly higher in the These results indicate that, compared to severely ill COVID-19 patients and to patients with fatal 580 outcomes, the asymptomatic COVID-19 patients presented significantly higher frequencies of co-infections 581 with α-CCCs strains, in general, and with the 229E strain of α-CCCs in particular. Fig. S4) . We hypothesized that this pre-existing response predating the 588 COVID-19 pandemic could possibly influence the establishment of the SARS-CoV-2-specific T cell response 589 either positively or negatively, and its effectiveness to prevent the most severe symptoms in infected patients.

Therefore, we investigated ( Fig. 8A ) a possible correlation between (i) the cross-reactivity of each epitope 591 measured in HD (i.e., the ability of each SARS-CoV-2 CD4 + and CD8 + -derived epitope to recall a SARS- 

Within the category of asymptomatic and mild COVID-19 patients, we found statistically significant 599 positive correlations (P > 0.001) between the epitope cross-reactivities measured in HD and the percentage 600 of asymptomatic and mild COVID-19 patients that developed a strong IFN-g + T cell response (SFCs>50) 601 specific to SARS-CoV-2-derived CD4 + T cell epitopes (Fig. 8A -upper graph, gray line) or CD8 + T cell 602 epitopes ( Fig. 8A -lower graph, gray line) . In contrast, no such significant correlations were found within 603 the category of patients with severe or fatal COVID-19 ( Fig.8 -black lines) . Similarly, we found a positive 604 correlation between epitopes cross-reactivities measured in HD and the corresponding slopes S calculated 605 from Figs. 1A and 1B (Supplemental Fig. S7A -upper graph for CD8 + epitopes and lower graph for CD4 + epitopes) (P<0.0001). Taken together, these results demonstrate that the cross-reactive SARS-CoV-2 607 epitopes that recalled the strongest CD4 + and CD8 + T cell responses in unexposed healthy donors (HD) 608 also recalled the strongest responses in asymptomatic COVID-19 patients and were the most highly 609 associated with better disease outcome.

To better understand the possible underlying causes of the observed T-cell cross-reactivity in HD,

we determined which of our SL-CoVs-conserved SARS-CoV-2-derived epitopes were also conserved within were highly conserved (% id ≥67%) and highly similar (S S ≥ 0.8) between SARS-CoV-2 and the α-CCCs 623 and/or β-CCCs strains. Specifically, the ORF1ab3013-3021 CD8 + T cell epitope was highly conserved between 624 SARS-CoV-2 and the two strains of β-CCCs (β-CCC-HKU1 and β-CCC-OC43); the ORF1ab6749-6757 epitope 625 was highly conserved between SARS-CoV-2 and all the four strains of CCCs; the S958-966 epitope was highly 626 conserved between SARS-CoV-2, the two β-CCCs strains and the α-CCC-NL63 strain; the E20-28 epitope 627 was highly conserved between SARS-CoV-2 and the β-CCC-HKU1 strain; and the M52-60 epitope was highly 628 conserved between SARS-CoV-2, the two β-CCCs strains and the α-CCC-229E strain (Supplemental Fig.   629 Tables 3 and 4) . While the E20-28 epitope was conserved (%id = 67%) between SARS-

CoV-2 and α-CCC-NL63 strain, it was not highly similar with the corresponding NL63 peptide (S S = 0.76).

Similarly, while the S976-984 epitope was conserved between SARS-CoV-2 and three CCCs strains (%id = 

(S S =0.78) and α-CCC-NL63 (S S = 0.73)). Finally, while the S2-10 epitope was highly similar between SARS-

CoV-2 and α-CCC-NL63 (S S = 0.82) it was not highly identical (id% = 56%) (Supplemental Tables 3 and 4) . 635 We next determined whether the SARS-CoV-2 epitopes identified above as sharing high identity and 636 similarity with epitopes in various CCCs were targeted preferentially by the CD4 + and CD8 + T cell responses 637 of either severely ill COVID-19 patients, or of asymptomatic COVID-19 patients (Fig. 8B) . By comparing the 638 slopes S ( Fig. 1 and 2) of the SARS-CoV-2-specific CD4 + and CD8 + T cell responses toward CD4 + /CD8 + 639 epitopes that have neither identical nor similar related peptides in any of the four CCCs (Fig. 8B -first blank 640 column) with the slopes of T cell responses specific to CD4 + /CD8 + epitopes that are highly similar and/or 641 identical (conserved) with at least one of the four CCCs (Fig. 8B -second blank column) , we could not find 642 any significant differences. By contrast, SARS-CoV-2 CD4 + or CD8 + T cell responses targeting epitopes 643 conserved (highly identical and similar) exclusively in β-CCCs but not in α-CCCs (i.e., epitopes ORF1ab5019-644 5033 and ORF1ab3013-3021) have a significantly lower slope S (P=0.04 - Fig. 8B ). In fact, those two epitopes 645 have their slopes S the closest to 0 among all epitopes (Supplemental Table 2 ) and were not significantly 646 correlated with less disease severity ( Figs. 1 and 2) . In conclusion, epitopes sharing high identity and 647 similarity exclusively with beta CCCs were targeted mainly by severely ill symptomatic patients.

In summary, these results indicate that: (i) asymptomatic patients and patients with mild COVID-19 649 preferentially developed strong IFN-g + CD4 + and CD8 + T cell responses toward the most cross-reactive SL- In the present study, we report that compared with the (non-vaccinated) asymptomatic COVID-19 661 patients developing little to no disease, the severely ill symptomatic patients that required admission to an 662 ICU and patients with fatal outcomes exhibited high frequencies of exhausted 663 PD-1 + TIM3 + TIGIT + CTLA4 + CD4 + and PD-1 + TIM3 + TIGIT + CTLA4 + CD8 + T cells, and low frequencies of 664 functional SARS-CoV-2-specific IFN-g + CD4 + and IFN-g + CD8 + T cells. Interestingly, compared to severely ill 665 COVID-19 patients and to patients with fatal outcomes, the asymptomatic COVID-19 patients were more 666 commonly co-infected with the a-CCCs strains, whereas there was no difference in the prevalence of co- and asymptomatic patients to demonstrate that high frequencies of phenotypically and functionally 683 exhausted CD4 + and CD8 + T cells specific to conserved epitopes were associated with severe symptoms in 684 critically ill patients and in patients with a fatal outcome.

We also report here that an early and broad lymphopenia positively correlated with COVID-19 686 disease severity and mortality, consistent with previous reports (66) . Moreover, our study also confirmed 687 previous reports of broad leukocytosis combined with T cell lymphopenia in severe COVID-19 patients and 688 extended those findings by demonstrating the observed T cell lymphopenia was particularly apparent for 689 SARS-CoV-2-specific T cells (11-15, 66, 67) . Moreover, compared with asymptomatic COVID-19 patients, 690 severely ill symptomatic patients and patients with fatal outcomes exhibited high frequencies of exhausted 691 PD-1 + TIM3 + TIGIT + CTLA4 + CD4 + and PD-1 + TIM3 + TIGIT + CTLA4 + CD8 + T cells. In contrast, the less severe 692 disease in asymptomatic and surviving patients inversely correlated with high frequencies of functional (less 693 exhausted) SARS-CoV-2-specific CD134 + CD137 + CD4 + and CD134 + CD137 + CD8 + T cells. Our results also 694 agree with a previous finding that showed increased levels of programmed cell death protein 1 (PD-1) in 695 severe cases compared to those in the non-severe cases (3). In addition, we extend those reports by 696 showing that the exhausted SARS-CoV-2-specific CD4 + and CD8 + T cells co-express TIM3, TIGIT, and 697 CTLA4 markers of exhaustion, besides PD-1. In addition, we detected low frequencies of SARS-CoV-2-698 specific IFN-g + CD4 + and IFN-g + CD8 + T cells in severely ill symptomatic patients with severe disease or fatal 699 outcomes. This finding confirmed previous reports of impaired cellular functionality in CD4 + and CD8 + T cells 700 in severe COVID-19 cases along with generally lower interferon gamma (IFN-g) and tumor necrosis factor 701 alpha (TNF-a) production (8, 16, 42, 73) . Our data indicates that, early after the onset of disease symptoms, 702 exhaustion of peripheral blood-derived SARS-CoV-2 specific CD4 + and CD8 + T cells might be a suitable 703 predictor of COVID-19 disease severity.

In the present study and as we previously reported (1), we detected pre-existing cross-reactive CD4 + 705 and CD8 + T cells specific to many of our SARS-CoV-2 epitopes in 15 healthy donors, who has never been 706 exposed to COVID-19 (Supplemental Fig. S4 severe COVID-19 the asymptomatic patients presented significantly higher frequencies of co-infections with 711 α-CCCs strains (Fig. 7) . Conversely, severely ill patients comparatively preferentially responded to SARS-CoV-2 epitopes cross-reacting with β-CCCs solely. Our data suggests that mechanisms of T cell exhaustion 713 may involve prior infections with b-strains of CCCs. It is likely that different repertoires of protective and 714 pathogenic SARS-CoV-2 specific T cells targeting cross-reactive epitopes from structural, non-structural, 715 and regulatory protein antigens are associated with different disease outcomes in COVID-19 patients (73, 716 75). One cannot rule out, however, that a rapid establishment of a-CCCs-cross-reactive SARS-CoV-2-717 specific CD4 + and CD8 + T cell responses resulting from previous exposure to a-CCC strain(s) induced 718 protective T cell immunity that led to less-severe COVID-19 disease. In contrast, b-CCCs-cross-reactive highest similarity scores) are not necessarily the same SARS-CoV-2 epitopes that recalled the strongest T cell responses in HD. For example, the SARS-CoV-2 epitopes ORF1a1350-1365, S1-13, all recalled strong CD4 + T cell responses in HD but have no identical nor similar related peptides in any of 741 the four CCCs. The same observation applies for the CD8 + epitopes ORF1ab1675-1683, S1000-1008 and S1220-1228 742 (Supplemental Fig. S4 and Supplemental Tables 3 and 4) . Interestingly, eight of the 27 CD8 + T cell 743 epitopes (ORF1ab1675-1683, ORF1ab5470-5478, ORF1ab6749-6757, S2-10, S958-966, S1220-1228, E20-28 and E26-34) shared 744 highly identical sequences (%id equal to 67% to 78%) and six of those also sharing high similarity scores 745 (S S ≥0.8) with predicted epitopes found in common human pathogens (EBV, Streptococcus pneumoniae,

Bordetella pertussis and Corynebacterium diphtheriae) and in widely distributed vaccines (BCG and 747 DTa/wP) (Supplemental Table 7 and Supplemental Table 4 ). The CD8 + T cell responses specific to SARS-

CoV-2 epitopes sharing high identity and similarity with DTwP vaccines -but not BCG vaccines-epitopes 749 were significantly more associated with less COVID-19 disease severity (Supplemental Fig. S7B ). These 750 findings suggests that the pre-existing cross-reactive T cell responses may not be the consequence of a 751 single mechanism, but rather could be shaped by antigens present in various pathogens (including CCCs) 752 and widely administrated vaccines (BCG, DTwP). Indeed, the most functional SARS-CoV-2 conserved CD8 +

T cell epitopes were highly similar and identical with epitopes from the DTwP vaccine (Supplemental Table   754 2 and 7). These findings are consistent with a previous study that described a correlation between DTwP leading to a reduction in antibody production over time (104, 105) . These concerns seem especially relevant 780 in the long term (106) symptoms. We are currently assessing in HLA-A2/DR1 hACE2 triple transgenic mice whether candidate 791 multi-epitope-based pan-SL-CoVs vaccines expressing the best "asymptomatic" epitopes that cross-react 792 with a-CCCs (i.e., excluding epitopes cross-reacting solely with b-CCCs) would induce better protection.

This study has certain limitations worth noting. First, the study did not follow up with the COVID-19 patients at later times during convalescence. Second, since the lymphopenia reported in this study was 795 assessed in the peripheral blood, this may not reflect tissue resident CD4 + and CD8 + T cells. Also, the 796 severity of COVID-19 disease and the higher mortality risks might be attributed to dysregulation of lung-797 resident SARS-CoV-2 specific CD4 + and CD8 + T cells, rather than peripheral blood T cells. Thus, further 798 studies will focus on lung tissue-resident SARS-CoV-2 specific CD4 + and CD8 + T cells to determine whether population. Nevertheless, our results seem to confirm the hypothesis underscored by others (7) information. We also thank those who contributed directly or indirectly to this COVID-19 project: Gavin S. percentages and ratios of total lymphocytes among WBCs (two right panels) measured ex-vivo by blood differential test (BDT) in COVID-19 patients (n = 147) who ended up with various severity of disease. discharged, patients were scored ("severity score", or "category of COVID-19 severity") on a scale from 0 to SARS-CoV-2 T cell epitopes sharing high identity and high similarity with epitopes from at least β-CCCs SARS-CoV-2 T cell epitopes sharing high identity and high similarity with epitopes from β-CCCs but not α-CCCs SARS-CoV-2 T cell epitopes sharing high identity and high similarity with epitopes from at least α-CCCs SARS-CoV-2 T cell epitopes sharing high identity and high similarity with epitopes from α-CCCs but not β-CCCs 

CD4(+), and CD8(+) T Cell Epitopes That Are Highly Conserved between Human and

Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus 836

Zoonotic origins of human coronaviruses

Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune 841 responses

Emergence of Bat-Related 843 Betacoronaviruses: Hazard and Risks

SARS-CoV-2 Omicron has 845 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for 846 infection

Characteristics of and important lessons from the coronavirus disease 848 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center 849 for Disease Control and Prevention

SARS-CoV-2-specific T cells in infection and vaccination

Clinical and immunological features of 853 severe and moderate coronavirus disease 2019

Pathogenic T cells and inflammatory monocytes 855 incite inflammatory storm in severe COVID-19 patients

Neutrophils and COVID-19: The road so far

Prognostic Value of Leukocytosis and Lymphopenia for 996

The role of IL-6/lymphocyte ratio in the 998 peripheral blood of severe patients with COVID-19

Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A 1002 Systematic Review and Meta-analysis

Limited TCR 1004 repertoire and ENTPD1 dysregulation mark late-stage COVID-19. iScience

A single-cell atlas 1006 of the peripheral immune response in patients with severe COVID-19. Nature medicine

Sustained cellular immune 1009 dysregulation in individuals recovering from SARS-CoV-2 infection

Single-cell landscape of immunological 1011 responses in patients with COVID-19

SARS-CoV-2-1013 specific T cell responses and correlations with COVID-19 patient predisposition

Broad and strong memory

CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Immunological 1022 imprinting of the antibody response in COVID-19 patients

Exhausted Cross-Reactive SARS-CoV-2-Specific T cells in Severely ill COVID-19 Patients 42

Do childhood colds help the body respond to COVID? Nature

Homologies between SARS-CoV-2 1025 and allergen proteins may direct T cell-mediated heterologous immune responses. Scientific reports

On BCG Vaccine Protection from COVID-19: A Review

A strategy to assess 1030 spillover risk of bat SARS-related coronaviruses in Southeast Asia

Biological and genetic characterization of a 1032 hemagglutinating coronavirus isolated from a diarrhoeic child

Exposure to SARS-CoV-2 generates T-1034 cell memory in the absence of a detectable viral infection

Related Coronavirus Infection in Humans, China

Novel Canine Coronavirus Isolated 1038 from a Hospitalized Patient With Pneumonia in East Malaysia

Temporary carriage of bovine 1040 coronavirus and bovine respiratory syncytial virus by fomites and human nasal mucosa after 1041 exposure to infected calves

Repeated 1043 Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection 1044 against Severe COVID-19

Bat SARS-Like WIV1 coronavirus uses the 1046 ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation 1047 of membrane fusion

Emergence 1049 of porcine delta-coronavirus pathogenic infections among children in Haiti through independent 1050 zoonoses and convergent evolution

Exhausted Cross-Reactive SARS-CoV-2-Specific T cells in Severely ill COVID-19 Patients 43

Comorbid illnesses are 1052 associated with altered adaptive immune responses to SARS-CoV-2

Prospect of SARS-CoV-2 spike protein: Potential role in 1054 vaccine and therapeutic development

Correlates of Neutralization 1056 against SARS-CoV-2 Variants of Concern by Early Pandemic Sera

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine 1058 Target: Structural Insights into Its Complexes with ACE2 and Antibodies

Potent neutralizing antibodies against multiple 1060 epitopes on SARS-CoV-2 spike

Safety and Efficacy of 1062 the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine

Efficacy and Safety of the mRNA-1065 1273 SARS-CoV-2 Vaccine. The New England journal of medicine

SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted 1070 tissue distribution

Decreased infectivity 1072 following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health Eur

Vaccine Breakthrough 1075 Infections with SARS-CoV-2 Variants

Escape from neutralizing 1077 antibodies by SARS-CoV-2 spike protein variants

Exhausted Cross-Reactive SARS-CoV-2-Specific T cells in Severely ill COVID-19 Patients 44

The success of SARS-CoV-2 vaccines and challenges ahead

SARS-CoV-2 variants B.1.351 1081 and P.1 escape from neutralizing antibodies

Unbiased Screens 1083

Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely 1084 Reside outside the Spike Protein

Antibody titres decline 1086 3-month post-vaccination with BNT162b2

Kinetics 1088 of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A 1089 Prospective Study in 283 Health Workers

Effectiveness of 1091 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: 1092 a retrospective cohort study. The Lancet

Age-related immune 1094 response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Common Variable 1096

1098 1099 0) were also called ASYMP (asymptomatic) whereas all the patients who developed symptoms 1317 (independently of the disease severity) were broadly categorized as SYMP. For SYMP patients who did not 1318 go to the ICU, we had: ED = patients who went to the Emergency Department, got screened COVID-19 but 1319 did not stay in the hospital for regular admission (severity 1)

Except 1321 for the age, the onset of symptoms, the WBCs and lymphocytes count and the total number of comorbidities, 1322 all the parameters displayed in the table (demographic features, HLA-genotyping, clinical parameters, and 1323 prevalence of comorbidities) represent the number of patients within each category of disease severity and 1324 the percentages in brackets (rebased to the total number of patients in the corresponding category). For the 1325 age parameter, median values are shown for each category of disease severity along with ranges

WBCs & lymphocytes counts are averages per µL of blood

HLA-genotyping, clinical 1330 parameters, onset of symptoms and prevalence of comorbidities of each of the 147 patients enrolled 1331 in the study: This table shows all the detailed information (age, sex, race/ethnicity, length of stay, HLA-1332 genotyping, all the experienced symptoms, symptoms onset and the potential comorbidities…) for each 1333 individual patient included in the study. Patients medical record numbers were anonymized by assigning 1334 each patient a code as follow: AS## for ASYMP patients and S### for SYMP patient

Supplemental Table 2: Detailed information and listing of the 27 class-I-restricted SL-CoVs-1336 conserved SARS-CoV-2-derived CD8 epitopes and the 16 class-II-restricted SL-CoVs

SARS-CoV-2 1339 corresponding protein, peptides amino-acid sequence, correlation coefficients R and Slopes S (from Fig 1C 1340 and 2C). S is used to assess (for each individual SARS-CoV-2 epitope) the magnitude of the correlation 1341 between the breadth of this epitope-specific T cell response measured in SARS-CoV-2 infected patients and 1342 the protection against severe COVID-19. The blue/red color code allows to visually compare different correlation magnitudes between the SARS-CoV-2 epitopes. For each SARS-CoV-2 epitopes

Supplemental Table 3: Best matching peptide sequence between SARS-CoV-2 epitopes and 1347

CCCs peptides, with identity percentages and similarity scores: CCCs peptides sequences

Details of the CCCs peptide selection method and similarity scores calculations 1350 are in Materials and Methods section, Supplemental Tables 5 and 6. The peptide similarity score "S s " 1351 calculation use here the BLOSUM62 matrix to compare a pair of peptides (peptide "x" from SARS-CoV-2 1352 and "y" from CCC) and is based on the Sune Frankild et al. methodology. 0 ≤ SS ≤ 1: the closest SS is to 1, 1353 the highest is the potential for T cell cross-reactivity response toward the related pair of peptides

Highlighted in yellow: following ECT analysis and compared to Supplemental Table 5 (MSA 1358 analysis), those are new hits of highly identical and/or similar CCC peptides for which either the % of identity 1359 is ≥ 67%

0: low to no potential for an CCC peptide to induce a cross-1365 reactive response toward the corresponding SARS-CoV-2 epitope and vice-versa i.e., %id with the 1366 corresponding SARS-CoV-2 epitope < 67% AND similarity score S S < 0.8; 0.5: there is a CCC peptide that 1367 may induce a cross-reactive response i.e., %id with the corresponding SARS-CoV-2 epitope ≥ 67% OR 1368 similarity score S S ≥ 0.8; 1: there is a CCC peptide very likely to induce a cross-reactive response i.e., %id ≥ 1369 67% AND S S ≥ 0.8. For identification of potential cross-reactive peptides with our SARS-CoV-2 epitopes in widely 1371 administrated vaccines and common human pathogen: details are in Supplemental Table 7

Supplemental Table 5: Aligned SARS-CoV-2 epitopes with CCCs peptides determined using 1376

Multiple Sequences Alignment -details and calculations for Supplemental Table 3: Corresponding 1377 CCC peptides were determined here after proteins sequences alignments of all four homologous CCCs 1378 proteins plus the SARS-CoV-2 related one using various Multiple Sequences Alignments algorithms

Results were 1382 also confirmed with global and local Pairwise alignments

In case of different results obtained with the various algorithms, the epitope sequence with the highest 1384 BLOSUM62-sum score compared to the SARS-CoV-2 epitope set as reference was chosen. For each pair 1385 of SARS-CoV-2-epitope / CCCs corresponding peptide, % of identity and similarity score were calculated

Supplemental Table 6: Matching epitopes between SARS-CoV-2 and CCCs determined using 1387

ECT) analysis -details and calculations for Supplemental Table 3: For 1388 each one of our 16 CD4 + and 27 CD8 + SARS-CoV-2 epitopes, we ran the ECT against the entire proteomes 1389 of each CCCs. All the CCCs peptides from the top query -i.e., with the highest % of identity -are

Supplemental Table 7: Analysis of potential SARS-CoV-2 cross-reactive epitopes in other 1392 non-coronavirus common pathogens and widely distributed vaccines -details for Supplemental 1393

Table 4: Query performed on the data gathered from "Potential Cross-Reactive Immunity to SARS-CoV

From Common Human Pathogens and Vaccines" by Pedro A. Reche in Frontier Immunol. Only the peptides 1395 sharing a % of identity ≥ 67% with the corresponding SARS-CoV-2 epitope were extracted and